Patients with end-stage renal disease have a heightened risk of cardiovascular morbidity and mortality. Cardiac arrest causes around one-quarter of deaths in this population, and a recent study has investigated whether echocardiographic parameters and serum biomarkers can be used to predict the risk of sudden cardiac death in patients on peritoneal dialysis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA (2010).
US Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA (2007).
Wang, A. Y. et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 56, 210–216 (2010).
Herzog, C. A. et al. Sudden cardiac death and dialysis patients. Semin. Dial. 21, 300–307 (2008).
Moss, A. J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346, 877–883 (2002).
Bardy, G. H. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225–237 (2005).
Apple, F. S. et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 106, 2941–2945 (2002).
Myerburg, R. J. et al. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation 97, 1514–1521 (1998).
Cice, G. et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J. Am. Coll. Cardiol. 41, 1438–1444 (2003).
Epstein, A. E. et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 51, 1–62 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R. Passman consults for and has received honoraria from Medtronic, St. Jude Medical. C. A. Herzog consults for and has received grant/research support from Amgen, consults for CorMedix, has received honoraria from UpToDate and is a stockholder/director with Boston Scientific, Cambridge Heart, and Johnson & Johnson.
Rights and permissions
About this article
Cite this article
Passman, R., Herzog, C. Sudden cardiac death: stratifying risk in dialysis patients. Nat Rev Nephrol 7, 133–135 (2011). https://doi.org/10.1038/nrneph.2010.166
Published:
Issue date:
DOI: https://doi.org/10.1038/nrneph.2010.166
